key: cord-0983874-5mrt27pv
authors: Koo, Grace; Anvari, Sara; Friedman, Debra L.; Zarnegar-Lumley, Sara; Szafron, Vibha; Kahwash, Basil M.; Onasch, K. Michelle; Hall, Laura; Phillips, Elizabeth J.; Stone, Cosby A.
title: mRNA COVID-19 Vaccine Safety in Patients with Previous Immediate Hypersensitivity to Pegaspargase
date: 2021-10-20
journal: J Allergy Clin Immunol Pract
DOI: 10.1016/j.jaip.2021.09.051
sha: 082207b174512e9a66b8abcf83cf896df4640049
doc_id: 983874
cord_uid: 5mrt27pv

nan

polyethylene glycol (PEG5000). 1 By itself, Escherichia coli-derived L-asparaginase is associated 76 with high rates of hypersensitivity reactions. 1 The pegylated form has extended half-life and 77 improved immunogenicity profile compared to the native form, resulting in lower rates of 78 hypersensitivity reactions. 1-2 Tolerance of pegaspargase following a hypersensitivity reaction to 79

Escherichia coli-derived L-asparaginase suggest different antigenic sites. 1 However, 80 pegaspargase is also commonly associated with immediate hypersensitivity reactions, with 81 incidence ranging from 3-41%. 3 Infusion reactions to pegaspargase might therefore be due to 82 PEG given the presence of anti-PEG antibodies in several studies, but may also be due to 83 reactivity against asparaginase itself. Reactions to pegaspargase are of an immediate 84 hypersensitivity phenotype, but the class of PEG-specific antibodies detected in these patients 85 have previously been reported as primarily IgG, not IgE. 4 IgE-mediated PEG allergy is rare, but 86 has been demonstrated with positive skin testing and elevated specific IgE levels. 5-7 Interestingly, 87 patients with immediate hypersensitivity to pegaspargase typically have subsequent tolerance to 88 PEG3350, which is routinely used to treat constipation associated with other chemotherapeutic 89 agents for ALL and LL. However, patients and clinicians maintain high vigilance toward the 90 possibility of cross-reactivity reactions to higher molecular weight PEG-containing products. We present a prospective case series of 19 patients who were candidates for the mRNA COVID-102 19 vaccine, but had a history of immediate hypersensitivity reactions to pegaspargase evaluated 103 at outpatient drug allergy clinics at Vanderbilt University Medical Center (VUMC) and Texas 104

Children's Hospital (TCH) between April 2021 and July 2021. After careful evaluation of the 105 index reaction history, each patient at VUMC underwent a standard skin testing protocol 106 containing PEG3350 (skin prick only 1.7mg/ml and 17mg/ml), PEG8000 (skin prick only 107 0.1mg/ml and 1mg/ml), and methylprednisolone acetate (skin prick and intradermal 4mg/ml and 108 0.4mg/ml), which contains PEG3350, as the primary agents of interest. In patients with negative 109 skin testing at VUMC, a direct challenge with Pfizer-BioNTech mRNA COVID-19 vaccine 0.5 110 ml was administered undiluted intramuscularly followed by a 1-hour observation to monitor for 111 any immediate reaction. At TCH, patients who reported a history of tolerance to PEG3350 were 112

given the option to receive the Pfizer-BioNTech mRNA COVID-19 vaccine followed by a 30-113 minute observation, without prior skin testing. Those who did not report a history of tolerance to 114 PEG3350 or who preferred to receive skin testing underwent a previously reported skin testing 115 protocol prior to recommendation of the vaccine. 8 116

The demographics, index reaction history, and testing results of the 19 patients are summarized 117 in Table 1 . Of the patients evaluated with the protocol above, 9 (47.4%) were female and the 118 average age was 16.5 years (range: 12 to 33 years). An average of 6. the mechanism behind immediate hypersensitivity reactions to pegaspargase does not typically 143 appear to be IgE-mediated. 4 In this case series, we provide further evidence that IgE-mediated 144 sensitization to PEG is unlikely to be the primary mechanism for pegaspargase immediate 145 hypersensitivity, as 2 patients reported subsequent tolerance to pegaspargase without symptoms, 146 16 patients reported consuming PEG3350 without any symptoms, and 14 patients had negative 147 skin testing, including 10 patients with negative prick testing to the higher molecular weight 148 PEG8000. The subsequent tolerance of pegaspargase in 2 cases highlights that the original 149 reaction was either not related to pegaspargase or was related to a non-IgE mediated mechanism; 150 our report does not differentiate between these possibilities. Allergenicity of PEG reportedly 151 increases as the density and molecular weight of PEG increases. Therefore, patients with IgE-152 mediated sensitization to PEG have been shown to lose sensitization to lower molecular weight 153 PEG before higher molecular weight PEG and reactivity to lower molecular weight PEG can be 154 variable. 9 The lack of evidence of any immediate reaction on either the first or second dose of the 155 Pfizer-BioNTech COVID-19 mRNA vaccines also does not support an IgE mechanism or 156 immunological resensitization to PEG as a result of immunization. 157

A limitation of our study is that we did not measure PEG IgE, IgM, or IgG prior to vaccination; 158 however, these antibody tests are not commercially available and have yet to be validated across 159 multiple populations in widespread studies. Serum tryptase levels were also not available for 160 evaluation. Another limitation is the majority of our patients experienced the pegaspargase 161 hypersensitivity reactions >5 years prior to the evaluation for the mRNA COVID-19 vaccines, 162 however, 9/19 (47%) patients were within 5 years of their original reaction. With lower expected 163 age eligibility for the vaccine, it will be important to evaluate if our results hold for those with 164 more recent pegaspargase reactions, who may still have IgM, IgG, or IgE PEG antibodies. This 165 is also important since the clinical relevance of IgM and IgG which is present at low levels in 5-166 9% of the population is not clear. Whether these patients might ever demonstrate anti-PEG sIgE 167 or positive PEG skin testing in the early pegaspargase reaction period remains unknown. 168

Beyond the ongoing mechanistic questions underlying pegasparagase reactions, we provide 169 preliminary supportive evidence that patients with a previous immediate reaction to 170 pegaspargase can be safely vaccinated with mRNA vaccines containing PEG2000. PEG skin 171 testing was intentionally completed in all patients evaluated at VUMC as part of the research 172 protocol and to determine the utility of skin testing prior to vaccine challenge, whether or not 173 patients subsequently tolerated PEG-containing products following their index reaction. As 174 demonstrated by the patients evaluated at TCH who did not undergo skin testing due to known 175 prior tolerance of PEG3350, PEG skin testing is unlikely to be necessary in that circumstance 176 prior to PEG-containing mRNA vaccines. In this population of patients with ALL in complete 177 remission our study was focused on COVID-19 vaccine safety. The objective of our evaluation 178 focused on determining whether patients with labels of immediate reactions to pegaspargase 179 could safely receive mRNA vaccines containing PEG 2000. To our knowledge, PEG testing in 180 pegaspargase reactors has not been reported previously. Since our focus was COVID-19 vaccine 181 safety we did not perform skin testing or challenges with pegaspargase and hence we acknowledge that we did not directly or specifically address the pegaspargase allergy which 183 remains as a warning in the patient chart. 184

In summary our case series of safe COVID-19 mRNA vaccination in ALL survivors with a 185 history of immediate reactions to pegaspargase provides reassurance that this is a safe strategy. 

L-asparaginase and PEG asparaginase--past, 205 present, and future

Pegaspargase: A Review in Acute Lymphoblastic 208

Severe 211 pegaspargase hypersensitivity reaction rates (grade ≥3) with intravenous infusion vs. 212 intramuscular injection: analysis of 54,280 doses administered to 16,534 patients on 213 children's oncology group (COG) clinical trials

Predict Pegaspargase Allergic Reactions and Failure of Rechallenge

Optimizing investigation of suspected allergy to polyethylene glycols

Anti-PEG IgE 225 in anaphylaxis associated with polyethylene glycol

Hypersensitivity to Polyethylene Glycols and Polysorbates: More Common Than We 230

Have Recognized

Vaccines to Prevent COVID-19 Disease and Reported Allergic Reactions: Current 234

Evidence and Suggested Approach

Optimizing investigation of suspected allergy to polyethylene glycols